The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 2nd 2023
Despite commonly understood symptoms and efficacious treatments, the stigmatizing nature of gout has caused significant setbacks to curbing its impact on Americans.
September 29th 2023
September 29th 2023
Clinical Consultations: Individualizing Management of Uveitic Macular Edema - Clinical Updates in Treatment Options
EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
Data from an analysis of kidney biopsies from the AURORA 2 trial presented at CCR East 2023 offer new insight into the long-term histological impact of voclosporin use on renal function in patients with lupus nephritis.
Often overlooked and underfunded, as well as being underpaid compared to internal medicine, it is difficult to convince prospective medical students, many of whom already have substantial debt, to choose a career in pediatric rheumatology.
Results of a recent study showed that the risk of pneumocystis jiroveci pneumonia (PJP) is low in patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), therefore discouraging the routine prescribing of PJP prophylaxis for this patient population.
Results of a recent review showed that adalimumab, etanercept, golimumab, and infliximab are effective and well-tolerated treatments options for patients with juvenile idiopathic arthritis.
Multivariable models indicated that improvements in the physical component score and mental component score could be predicted by better self-efficacy scores in patients with systemic lupus erythematosus.
Patients with juvenile idiopathic arthritis were at a greater risk of developing autoimmune thyroid disease if they were female, reported ANA and/or RF positivity, and a family history of thyroid disease.
“Reversing and preventing adverse lifestyle factors could potentially reduce the incidence and burden of rheumatoid arthritis, as well as alleviate its comorbidities,” investigators hypothesized.
Investigators measured pain intensity, the primary outcome, as well as physical function, isometric strength, quality of life, and fibromyalgia impact at baseline and the 6-month mark.
“Our primary motivation was to help develop treatments for people with osteoarthritis that would slow or prevent the disease and be more than painkillers- actually affect the disease process itself,” Virginia Kraus, MD, explains.
General practitioners and rheumatologists were viewed as sources of information that led to positive views toward vaccinations, while internet chatrooms, social media, and mainstream media were seen as sources of information that led to negative views.
P38 mitogen-activated protein kinase (p38 MAPK) inhibitors have been a focal point for inflammatory diseases but the lack of efficacy in treating rheumatoid arthritis led to examination of the MK2 pathway.
The multicenter superiority trial evaluated patients with diagnosed knee osteoarthritis and a history of pain and decreased knee function using patient-tailored exercise programs.
Secukinumab therapy was associated with inhibition of joint tenderness and swelling, but high baseline radiographic damage was associated with reduced likelihood of full inhibition.